Creation of SPINOFF COMPANIES

Since the year 2000, ALIGO has played a role in creating over 71 Quebec-based technology companies. Of these 71 companies, 44 are still active, which equates to 62%, one of the highest percentages seen in this field. The 44 companies which are still active today have generated over $522 million in investments. The following image presents the companies in accordance with the size of their investments, both public and private.

Spinoff companies means:

  • A company incorporated for the main purpose of operating a license for a technology that Aligo is developing and which comes from an establishment that Aligo represents;
  • An already existing company that refocuses its activities around a license obtained from a technology that is valued by Aligo and that comes from an establishment that Aligo represents.

Representation on March 31, 2018

OUR SPINOFF COMPANYS

Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the blood-brain-barrier to treat neurological diseases.

AEPONYX Inc.

AEPONYX is a fabless micro optical switch semiconductor chips designer and manufacturer. AEPONYX chips are targeted at fiber optic access to the Cloud and optical switching in the Cloud. AEPONYX is creating a unique platform that can support the next generation of optical communications. AEPONYX’s micro optical switches are 100x faster, 10x cheaper and 10x […]

Reflex Photonics

Reflex Photonics is an advanced developer of rugged high-speed optical transceiver modules and parallel embedded optics products for aerospace, defense, avionics, telecom, and data centers. Our products enable equipment developers to design smaller, lower cost, and lower powered systems resulting in higher fidelity and faster connectivity.

Ovensa

Ovensa is a preclinical stage company working to fight inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics through its proprietary TRIOZAN™ Platform. The company focuses on advancing its lead nanotherapeutic candidate that synergistically improves efficacy of chemotherapy and checkpoint inhibitors in glioblastoma.

DropGenie

DropGenie is a biotechnology company developing a platform that automates liquid handling and experimental conditions specific to genetic engineering, thus reducing costs while improving standardization and reproducibility. With the rapid adoption of CRISPR technology, their product will initially target R&D applications by easing gene editing in human cells, followed by a longer term translational vision […]